Takeda Pharmaceutical Company Limited Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
Takeda Pharmaceutical Company Limited (TKPHF) reported Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of JPY 72.87 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2025-06-25
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|
| 2025-03-31 | 72.87B JPY 20-F · filed 2025-06-25 |
| 2024-03-31 | 70.87B JPY 20-F · filed 2025-06-25 |
| 2023-03-31 | 60.67B JPY 20-F · filed 2025-06-25 |
| 2022-03-31 | 43.37B JPY 20-F · filed 2024-06-26 |
| 2021-03-31 | 37.66B JPY 20-F · filed 2023-06-28 |
| 2020-03-31 | 29.12B JPY 20-F · filed 2022-06-29 |
| 2019-03-31 | 20.08B JPY 20-F · filed 2021-06-29 |
| 2018-03-31 | 18.61B JPY 20-F · filed 2020-06-24 |
| 2017-03-31 | 15.38B JPY 20-F · filed 2019-06-27 |